Summary

U.S. Artificial Organs And Bionics Market Summary

The U.S. artificial organs and bionics market size was estimated at USD 15.35 billion in 2024 and is projected to reach USD 30.11 billion by 2033, growing at a CAGR of 7.7% from 2025 to 2033. The market growth is attributed to the increasing number of transplants and the rising number of people waiting for donors.

In 2023, as reported by the Human Resource and Services Administration, the national transplant waiting list in the U.S. exceeded 104,000 individuals. Currently, a new name is placed on the waiting list every ten minutes, underscoring the increasing need for artificial medical devices to address unmet demand. This includes various devices designed to restore function or fully replace failed organs. The National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health (NIH), actively supports the development of these technologies to help people live healthier, more independent lives.

The U.S. government plays a key role in fostering innovation in the U.S. artificial organs and bionic industry through significant funding for research. The NIH, through its various institutes such as the National Institute of Neurological Disorders and Stroke (NINDS), has funded research into next-generation neural prosthetics that can restore movement and sensation by using a computerized interface.

U.S. Artificial Organs And Bionic Market Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. artificial organs and bionic market report based on product and technology:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Artificial Organs
o Kidney
o Heart
o Liver
o Lungs
o Pancreas
• Bionic
o Cochlear Implant
o Exoskeleton
o Bionic Limbs
o Brain Bionic
o Vision Bionic
• Technology Outlook (Revenue, USD Billion, 2021 - 2033)
• Mechanical
• Electronic

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product
2.2.2. Technology
2.3. Competitive Insights
Chapter 3. U.S. Artificial Organs and Bionic Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Artificial Organs and Bionic Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. U.S. Artificial Organs and Bionic Market: Pipeline Analysis
Chapter 4. U.S. Artificial Organs and Bionic Market: Product Estimates & Trend Analysis
4.1. Product Segment Dashboard
4.2. U.S. Artificial Organs and Bionic Market: Product Movement Analysis
4.3. U.S. Artificial Organs and Bionic Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Billion)
4.4. Artificial Organs
4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Billion)
4.4.1.1. Kidney
4.4.1.1.1. Market estimates and forecasts, 2021 to 2033 (USD Billion)
4.4.1.2. Heart
4.4.1.2.1. Market estimates and forecasts, 2021 to 2033 (USD Billion)
4.4.1.3. Liver
4.4.1.3.1. Market estimates and forecasts, 2021 to 2033 (USD Billion)
4.4.1.4. Lungs
4.4.1.4.1. Market estimates and forecasts, 2021 to 2033 (USD Billion)
4.4.1.5. Pancreas
4.4.1.5.1. Market estimates and forecasts, 2021 to 2033 (USD Billion)
4.5. Bionics
4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Billion)
4.5.1.1. Cochlear Implant
4.5.1.1.1. Market estimates and forecasts, 2021 to 2033 (USD Billion)
4.5.1.2. Exoskeleton
4.5.1.2.1. Market estimates and forecasts, 2021 to 2033 (USD Billion)
4.5.1.3. Bionic Limbs
4.5.1.3.1. Market estimates and forecasts, 2021 to 2033 (USD Billion)
4.5.1.4. Brain Bionic
4.5.1.4.1. Market estimates and forecasts, 2021 to 2033 (USD Billion)
4.5.1.5. Vision Bionic
4.5.1.5.1. Market estimates and forecasts, 2021 to 2033 (USD Billion)
Chapter 5. U.S. Artificial Organs and Bionic Market: Technology Estimates & Trend Analysis
5.1. Technology Segment Dashboard
5.2. U.S. Artificial Organs and Bionic Market: Technology Movement Analysis
5.3. U.S. Artificial Organs and Bionic Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Billion)
5.4. Mechanical
5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Billion)
5.5. Electronic
5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Billion)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company/Competition Categorization
6.3. Vendor Landscape
6.3.1. Key company heat map analysis, 2024
6.4. Company Profiles
6.4.1. ABIOMED
6.4.1.1. Company overview
6.4.1.2. Financial performance
6.4.1.3. Product benchmarking
6.4.1.4. Strategic initiatives
6.4.2. Berlin Heart
6.4.2.1. Company overview
6.4.2.2. Financial performance
6.4.2.3. Product benchmarking
6.4.2.4. Strategic initiatives
6.4.3. SynCardia Systems, LLC
6.4.3.1. Company overview
6.4.3.2. Financial performance
6.4.3.3. Product benchmarking
6.4.3.4. Strategic initiatives
6.4.4. BiVACOR Inc.
6.4.4.1. Company overview
6.4.4.2. Financial performance
6.4.4.3. Product benchmarking
6.4.4.4. Strategic initiatives
6.4.5. Cochlear Ltd.
6.4.5.1. Company overview
6.4.5.2. Financial performance
6.4.5.3. Product benchmarking
6.4.5.4. Strategic initiatives
6.4.6. Ekso Bionics
6.4.6.1. Company overview
6.4.6.2. Financial performance
6.4.6.3. Product benchmarking
6.4.6.4. Strategic initiatives
6.4.7. Edwards Lifesciences Corporation
6.4.7.1. Company overview
6.4.7.2. Financial performance
6.4.7.3. Product benchmarking
6.4.7.4. Strategic initiatives
6.4.8. Boston Scientific Corporation
6.4.8.1. Company overview
6.4.8.2. Financial performance
6.4.8.3. Product benchmarking
6.4.8.4. Strategic initiatives
6.4.9. Jarvik Heart, Inc
6.4.9.1. Company overview
6.4.9.2. Financial performance
6.4.9.3. Product benchmarking
6.4.9.4. Strategic initiatives
6.4.10. Medtronic
6.4.10.1. Company overview
6.4.10.2. Financial performance
6.4.10.3. Product benchmarking
6.4.10.4. Strategic initiatives